Sign Up for Free!

Continue Analyzing the page and more.

Continue with Google

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Upgrade to Pro
Home Daily Intelligence Tracker
    • Plans Blog Contact
    DiaMedica Therapeutics Inc logo
    DMAC

    DiaMedica Therapeutics Inc

    MaveScore 14 Low model confidence
    Last Price US$5.64 As of Jun 15, 2026
    Market Cap US$318.4m Company size context
    7D Performance 0.80% Past 7 days
    1Y Performance 34.29% Past 12 months
    Model Rating
    Historical model output for research review

    Fundamental data date

    Mar 31, 2026

    76 days old

    Market price date

    Jun 15, 2026

    1 day old

    Coverage

    16/16

    No missing model inputs

    Data quality

    Excellent

    Current stored snapshot

    Transparent research score

    Why the model scores this stock

    MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

    MaveScore 14 Low confidence

    Stored data quality

    Freshness and coverage checks

    Latest stored fundamentals and price inputs are recent enough for normal research review.

    16/16 Current stored snapshot

    Quality

    Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.

    8/35 Weak

    Financial Strength

    Financial strength rewards durable profitability, margins, and positive free cash flow.

    6/25 Weak

    Valuation Support

    Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.

    0/15 Weak

    Momentum

    Momentum highlights research candidates with supportive 3-month and 6-month price regimes.

    0/15 Weak

    Shareholder Alignment

    Shareholder alignment rewards less dilutive share behavior and enough size for liquid research coverage.

    0/10 Weak

    Positive model output

    More live company inputs are needed before positive research signals can be surfaced.

    Research risks to review

    • Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.
    • Financial strength rewards durable profitability, margins, and positive free cash flow.
    • Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting.

    Overview Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Ratio
    Dashboard Funda..tals Deep..lue Prediction Screener Map

    DiaMedica Therapeutics Inc Overview

    Industry: Biotechnology

    Sector: Healthcare

    DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

    DiaMedica Therapeutics Inc is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.

    Score

    Price History & Performance

    Review DiaMedica Therapeutics Inc in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.

    Recent News



    News Image
    DMAC: Cantor Fitzgerald Initiates Coverage with Overweight Ratin
    32 minutes ago
    News Image
    Will NanoViricides Inc. stock boost dividends further - Quarterly Performance Summary & Weekly Momentum Stock Picks
    2 hours ago
    News Image
    DiaMedica Therapeutics Reports Q3 2025 Financial Results
    11 hours ago

    DiaMedica Therapeutics Inc Competitors

    DiaMedica Therapeutics Inc operates in the Biotechnology industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.

    Earnings Per Share

    EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.

    Continue the analysis

    Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.

    View plans
    Ticker Image

    DiaMedica Therapeutics Inc

    US$5.64

    US$318.4m

    0.80%

    34.29%